The US Food and Drug Administration defended the federal government’s recent decision to stretch out its limited supply of the Jynneos monkeypox vaccine by giving individuals smaller doses using a different method of injection, pointing out in a letter to the company that manufactures the vaccine that a 2015 clinical study showed “a very similar immune response” to the new method as well as the previously used one.